Zydus Lifesciences Ltd. Q4 FY2026 results: revenue ₹7,587 crore, up 16.2% on the year
Zydus Lifesciences Ltd. (ZYDUSLIFE) reported consolidated revenue from operations of ₹7,587 crore for Q4 FY2026, the quarter ended 31 March 2026, up 16.2% on the same quarter a year earlier. Profit after tax was ₹1,341 crore, up 7.8% on the year, and earnings per share ₹12.65. The figures are the company's own, from the un-audited results it filed with NSE on 19 May 2026.
The quarter, against the one before and a year earlier
| Line | Q4 FY2026 | Q3 FY2026 | Q4 FY2025 | Change on the year |
|---|---|---|---|---|
| Revenue from operations | 7,587 | 6,864 | 6,528 | +16.2% |
| Other income | 134 | 111 | 81 | +66.5% |
| Total income | 7,721 | 6,976 | 6,608 | +16.8% |
| Cost of materials consumed | 1,347 | 1,216 | 1,164 | +15.7% |
| Purchases of stock-in-trade | 972 | 852 | 573 | +69.7% |
| Changes in inventories | -343 | -232 | -40 | n/a |
| Employee benefit expense | 1,239 | 1,140 | 971 | +27.5% |
| Finance costs | 123 | 130 | 77 | +60.6% |
| Depreciation, depletion and amortisation | 508 | 360 | 238 | +113.7% |
| Other expenses | 2,462 | 2,236 | 1,694 | +45.3% |
| Total expenses | 5,664 | 5,538 | 4,717 | +20.1% |
| Profit before exceptional items and tax | 2,057 | 1,438 | 1,892 | +8.8% |
| Exceptional items | -398 | -85 | -220 | n/a |
| Profit before tax | 1,660 | 1,353 | 1,672 | -0.7% |
| Current tax | 526 | 244 | 991 | -46.9% |
| Deferred tax | -207 | 144 | -567 | n/a |
| Total tax | 318 | 388 | 423 | -24.8% |
| Profit after tax | 1,341 | 1,023 | 1,244 | +7.8% |
| Attributable to owners of the parent | 1,272 | 1,042 | 73 | +1647.9% |
| Other comprehensive income | -483 | -22 | -23 | n/a |
| Total comprehensive income | 858 | 1,001 | 1,221 | -29.8% |
| EPS, basic | ₹12.65 | ₹10.36 | ₹11.64 | +8.7% |
| EPS, diluted | ₹12.65 | ₹10.36 | ₹11.64 | +8.7% |
₹ crore except per share.
Segments, Q4 FY2026
| Segment | Revenue ₹ crore | Share of segment revenue | Result ₹ crore | Result over revenue |
|---|---|---|---|---|
| Pharmaceuticals | 5,776 | 76.1% | 1,940 | 33.6% |
| Consumer products | 1,483 | 19.6% | 176 | 11.9% |
| Medical technologies | 328 | 4.3% | -59 | -18.0% |
Segment revenue and segment result as the company filed them, before inter-segment eliminations; share and result over revenue are arithmetic on those.
Balance sheet at 31 March 2026
| Q2 FY2026 | Q4 FY2026 | |
|---|---|---|
| Equity capital | 101 | 101 |
| Reserves | 25,201 | 27,011 |
| Equity, owners of the parent | 25,302 | 27,111 |
| Non-controlling interest | 2,788 | 2,471 |
| Borrowings | 9,594 | 11,770 |
| Total liabilities | 18,807 | 22,824 |
| Fixed assets | 7,099 | 9,231 |
| Capital work in progress | 1,190 | 1,166 |
| Goodwill and intangibles | 13,249 | 14,875 |
| Investments | 4,735 | 6,373 |
| Inventories | 4,750 | 5,628 |
| Receivables | 4,963 | 5,416 |
| Cash and bank balances | 2,782 | 1,417 |
| Total assets | 46,897 | 52,407 |
From the statement of assets and liabilities in this filing, beside the one before it (30 September 2025). Borrowings, investments and cash each add the current and non-current lines as filed.
Cash flow, 1 April 2025 to 31 March 2026
| Q4 FY2026 | |
|---|---|
| Cash from operating activities | 2,117 |
| Purchase of fixed assets | 3,394 |
| Free cash flow | -1,277 |
| Cash from investing activities | -8,296 |
| Borrowings raised | 8,260 |
| Borrowings repaid | 968 |
| Dividends paid | 1,106 |
| Interest paid | 354 |
| Buyback | 0 |
| Cash from financing activities | 5,997 |
| Net change in cash | 28 |
From the cash flow statement in this filing, for the fiscal year to this date. Free cash flow is cash from operations less the purchase of fixed assets, arithmetic on the two filed lines.
Quarterly results, the last 12 quarters
| Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,369 | 4,505 | 5,534 | 6,208 | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,864 | 7,587 | 8,017 |
| Expenses | 3,416 | 3,617 | 4,143 | 4,371 | 4,034 | 4,142 | 4,717 | 4,808 | 4,511 | 5,538 | 5,664 | 6,798 |
| Operating profit | 1,146 | 1,102 | 1,631 | 2,084 | 1,461 | 1,388 | 2,126 | 2,088 | 2,016 | 1,816 | 2,554 | 1,929 |
| OPM % | 26% | 24% | 29% | 34% | 28% | 26% | 33% | 32% | 33% | 26% | 34% | 24% |
| Other income | 54 | 38 | 156 | 63 | 68 | 58 | 81 | 155 | 109 | 111 | 134 | 106 |
| Interest | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 | 130 | 123 | 156 |
| Depreciation | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 | 360 | 508 | 555 |
| Exceptional items | 0 | 0 | 0 | 0 | 0 | 0 | -220 | 0 | -34 | -85 | -398 | -18 |
| Profit before tax | 1,007 | 926 | 1,547 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,307 |
| Tax % | 22% | 23% | 21% | 23% | 29% | 15% | 25% | 23% | 27% | 29% | 19% | 27% |
| Net profit | 803 | 790 | 1,246 | 1,482 | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 |
| EPS in ₹ | ₹7.91 | ₹7.80 | ₹11.69 | ₹14.11 | ₹9.06 | ₹10.17 | ₹11.64 | ₹14.58 | ₹12.51 | ₹10.36 | ₹12.65 | ₹9.35 |
| Filing | NSE | NSE | NSE | NSE | NSE | NSE | Filing | Filing | Filing | Filing | Filing | Filing |
₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company.
Source
Un-audited consolidated results for the quarter ended 31 March 2026, filed with NSE on 19 May 2026: the result statement. All of Zydus Lifesciences Ltd.'s results: NSE company page.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.